Hot Topics in HIV. Barcelona 2018
|
|
- Grant Pierce
- 5 years ago
- Views:
Transcription
1 Hot Topics in HIV. Barcelona 2018 Paving the way to an AIDS-free World. Mario Stevenson, PhD. Department of Medicine.
2 Reproductive Cycle of HIV and Sites of Action of Major Classes of Antiretroviral Medications (25 options) Fusion Inhibitors CCR5 Antagonists Reverse Transcriptase Inhibitors (RTI) Nucleoside RTI (NRTIs) Nonnucleoside RTI (NNRTIs) Integrase strand transfer inhibitors (INSTI) Protease inhibitors (PI) Gandhi M, Gandhi RT. N Engl J Med 2014;371:
3 Closing the Gap : Life Expectancy With current ART, 20 yo HIV+ adult is expected to live into their early 70s Mid-point life expectancy at age 20 Lower life expectancy in patients who start ART with CD4 count <350 Non-whites and IDUs also have shorter lifeexpectancies Samji H et al, PLoS One, 2013
4 What is driving the search for a cure? Current therapies are extremely effective - reduced pill burden, fewer side effects. Virus in blood can be reduced to undetectable levels for years. Why not maintain the status quo and go with life-long ART?
5 Why do people want to be cured?
6 Aside from the personal perspective, limitations in ART drive a global rationale for cure Courtesy: Steve Deeks
7 Despite massive global investment, less than 50% of global population is on ART with an undetectable viral load Sustained virus control is even less common A major limitation with current therapeutic strategies is the need to access and adhere to daily intervention for many decades
8 Global ART, in its current form, is still an elusive target. Long-acting antiretroviral formulations will improve adherence With more effective ART, will there still be a robust rationale for a practical and scaleable cure?
9 HIV Cure versus Remission No virus No stigma Impossible to prove Virus persists Stigma, inflammation Much easier to achieve Courtesy: Steve Deeks
10 What are the viable strategies by which a cure or remission might be achieved?
11 Viable pathways toward a durable remission/cure Gene and cell-based therapy Shock and kill Block and lock Early ART Remission (immunotherapy)
12 Gene and Cell-based Therapies
13 Viable pathways toward a durable remission/cure Gene and cell-based therapy Proof of concept: Berlin Patient Allogeneic stem cell transplant: several nearcures Multiple feasible pathways, including direct excision of provirus Will this ever be scalable on a global level and safer than ART? Targeting of infected cells will be challenging
14 Gene Therapy for HIV- no specific markers on latently infected cells to enable specific vector targeting
15 Shock and Kill
16 Viable pathways towards a durable remission/cure: Shock and kill Multiple latency reversing agents (LRAs) tested: effect is modest at best and inconsistent Basic discovery aimed at identifying novel pathways or combinations
17 Multiple latency reversal agents active in vitro Kim, Anderson and Lewin. Cell Host Microbe 2018 An alternate strategy involves locking down proviral activity
18 Block and Lock
19 Viable pathways toward a durable remission/cure Block and lock Most proviruses are difficult to reactivate ex vivo Permanent latency may be inducible by inhibiting tat or several host pathways, including mtor
20 Early ART
21 Viable pathways towards a durable remission/cure: Early ART Prevention of latency Preservation of immune function Post-treatment control
22 Can early ART prevent the establishment of a latent reservoir, leading to a cure?
23 Can early ART prevent the establishment of a latent reservoir, leading to a cure?
24 If no durable and sustained host response is present, a single virus can cause acute infection at any time, posing major risk to the individual and his or her sexual partners
25 Very early ART reduces the reservoir but is not curative N=8; ART in Fiebig I for >96 weeks; VL<50 c/ml; CD4>400 cells/ul Ananworanich J et al., CROI2017, Seattle, WA
26 Immunotherapy Encouragement from monkey but not human studies
27 Curing monkeys has proven to be relatively easy
28 Some (10% to 25%) of people who start therapy early (but not too early) and remain on therapy for years will exhibit at least partial control after ART is interrupted May occur in chronic infection (rare) No biomarker Mechanism unknown Low reservoir size, low T cell activation Classic CTL responses low, in contrast to elite controllers Non-cytolytic NK cell responses
29 Studies of elite control, post-treatment control, and postvaccine control all suggest that the immune system can effectively control HIV but mechanisms remain undefined Antibodies Dendritc Cells T cells NK Cells Courtesy: Steve Deeks
30 Immunotherapy for HIV infection Two decades of largely failed approaches Weak immunogenicity Pre-existing immuno-dominant responses that are dysfunctional CTL escape Inflammation and counter-regulatory immunosuppression High virus burden Immune-privileged tissue sanctuaries
31 Immunotherapy to enhance T cell function
32 Similarities between HIV persistence and cancer HIV Cancer Increased immune checkpoint markers on antigen-specific cells Epigenetically programmed exhausted T-cells (Tex) Reduce antigen burden Antiretroviral therapy Chemotherapy Radiotherapy Surgery Long lived forms Slow cycling Indefinite proliferative potential HIV latency Cancer stem cells Sharon Lewin
33 Latent HIV is enriched in CD4+ T-cells that express PD1, TIM3 and TIGIT CD8+ T cell dysfunction reversed in HIV-infected individuals on ART ex vivo with inhibitors of PD-1, CTLA-4 and TIGIT
34 Tissue sanctuaries Follicular disruption
35 B cell follicles: a relative sanctuary and may be a site for cryptic replication CD20 antibodies and IL-15 may break down barrier Fukazawa et al., Nature Med 2015; Banga et al., Nature Med 2016; Leong et al., Nature Immunol 2016
36 Supplemental Figure 1 CD8 and CD20 staining of axillary lymph node (Rh24827) CD20 (white) and CD8 + (red) staining of axillary node B cell follicle: a relative sanctuary for HIV as CD8+ effector T cells are excluded from B cell
37 Where are we in 2018?
38 HIV Cure 2018: Elimination and cure Reducing the reservoir size is possible with early ART and transplantation but the effect is incomplete and not scalable Proof-of-concept exists for most steps in the shock and kill strategy but this approach is not expected to be fully curative Block and lock remains promising but has yet to be tested in the clinic
39 HIV Cure 2018: Immunotherapy and remission Using immunotherapy (particularly in combination) to reduce and control the reservoir may be the most promising approach Post-treatment control provides proof-of-concept that a durable and effective host response can be induced therapeutically Cancer immunotherapy provides further evidence that the immune system can be retrained to effectively target rare diseased cells that exist in hard-to-reach tissues Correlates of control unknown, making treatment interruptions the only interpretable outcome
40 HIV Cure : Target Product Profile Efficacy: aviremia in absence of therapy > 2 years; early failure is tolerable, late failures must be rare Product: administered for limited period of time (e.g., 6 months); specialized (tertiary) care not required Target Population: effective ART initiated at any stage and in all populations Long-term safety: comparable to ART, transmission risk negligible Cost: < $1400 (RLS)
41 Health care expenditure in Africa is far below other nations
42 Is a global HIV cure realistic? The realities of global ART leave millions vulnerable and drive the rationale for curing, rather than treating, infection. Advances in long term formulation may offer a safer, scaleable and more practical solution, particularly in LMICs
43
44 HIV Cure Research in Africa Increasing cure research in Africa is urgently needed What do those living with HIV in Africa want from a cure? Will remaining antibody-positive remain a key source of stigma? What will a cure need to cost to be effective? What can be practically given in non-urban health care clinics? Will HIV subtype have an impact on the effectiveness of current cure interventions? Most vaccines are based on subtype B Will host factors unique to to the dominant African population be important? Current studies enrolled older, primarily white men-who-have-sex-with men who have been on long-term ART (decades) Will persistent inflammation be a concern? Will common prevalent co-infection affect or preclude the use immunotherapy?
45 Delivery of potent neutralizing antibodies using AAV The only protein expressed from AAV vector comes from the transgene put into it Proven ability to achieve long-term expression of the transgene product Outstanding safety record in human gene therapy trials Little or no integration of AAV vector DNA into host genome sequences
46 Delivery of potent neutralizing antibodies using AAV An SHIV-infected monkey The was only protein injected expressed with from AAV AAV expressing two potent antibodies vector comes from the transgene put into it One year later, the monkey has been cured! This is unexpected given Proven what ability we to think achieve we long-term know expression of the transgene product about how HIV persists in the body Outstanding safety record in human gene therapy trials Little or no integration of AAV vector DNA into host genome sequences
47 20 adults (and one child) who started therapy early (but not in hyperacute stage), remained on therapy for years, and had no rebound after stopping therapy Virus still remains detectable in blood but under control-even in absence of ARTfunctional cure?
48 Mississippi baby born to an HIV-positive mother who had not received antiretroviral treatment during pregnancy. Infant was treated from 30 hours after birth but parents stopped therapy after 18 months. Infant remained off drugs for next 27 months yet virus remained undetectable in blood until virus rebounded two months shy of infant s 4 th birthday.
49 44 million HIV infections; 1 validated cure, Timothy Brown (Berlin Patient) What was different about this case?
50 44 million HIV infections; 1 validated cure, Timothy Brown (Berlin Patient) Infected On ARVs until 2006 where he develops acute myeloid leukemia. Fails chemotherapy then receives two bone marrow transplants from a donor who had a mutation in CCR5- a co-receptor for the virus. 8 years later, virus is undetectable in all tissues even though Timothy Brown is not on therapy.
51 How was the Berlin Patient (Tim Brown) Cured? Total body irradiation, anti-thymocyte globulin, graft vs. host disease may have eliminated virus producing cells Donor cells may have been protected from HIV because of lack of CCR5 (coreceptor) CCR5 -/- TBI GvH ATG Slide courtesy R Gandhi Chronically producing cell How do we apply the lessons from this cure without incurring risks of stem cell transplant?
52
53 Lesson: not being able to detect HIV doesn t mean it s not there! We need more sensitive and accurate measures.
54 While there has been one hit and some near misses, these examples have galvanized the field to develop a cure for HIV-1 infection!
55 Strategies for eliminating HIV-1 infection!
56 What do I need to do to be cured of HIV? Current Cure Strategies Induce HIV expression to make cells vulnerable to clearance Enhance elimination of HIV expressing cells Stimulation & recruitment of CD8+ CTLs, Monocytes, NKs Y Y Effector antibodies targeted to cells expressing HIV envelope Modify host CD4 cells to make them impervious to HIV Courtesy of John Mellors
57 Fold HIV induction Combination Latency Reversing Agents (LRA): More Effective Induction of HIV expression Single LRA Combo LRA HDAC inhibitor + protein kinase C (PKC) agonist more effective at inducing HIV expression than either is alone However, concerns regarding toxicity of PKC agonists. Laird G et al JCI, 2015
58 TLR-7 Agonist Toll-like receptor-7 (TLR-7) Expressed by plasmacytoid dendritic cells and B cells TLR-7 agonist: Enhances NK, T and B cell activation Induces HIV expression Promising results in SIV+ ART-treated macaques Now in human trials Whitney Nature Med 2018 V1 V When ART stopped, 2 of 9 animals did not have SIV rebound 1. Induces SIV viremia (LRA) Vehicle No stimulation Pre-TLR7 Post 10th Post 19th Post 19th No stimulation Pre-TLR7 Post 10th Post 19th Post 19th No stimulation Pre-TLR7 Post 10th Post 19th Post 19th Reduces SIV reservoir No stimulation Pre-TLR7 Post 10th Post 10th Placebo GS-986 (0.1mg/kg) GS-9620 (0.05mg/kg) GS-9620 (0.15mg/kg) 7 PBMC LN PBMC LN PBMC LN PBMC LN ConA ConA ConA ConA 0 Post 10th
59 Modify CD4 cells to make them impervious to HIV (Gene Therapy) Infusion of autologous CD4 cells in which CCR5 gene (encodes HIV coreceptor) excised by zinc-finger nuclease Modified CD4 cells: half-life 48 wks Modified cells decline less during ART interruption than unmodified cells ( 1.8 vs cells/day) During ATI, HIV RNA undetectable in 1 participant (heterozygous for CCR5 delta 32) Modifying CD34+ hematopoietic Stem/Progenitor Cells with anti-hiv Gene Transfer Construct and fusion inhibitor CRISPR/Cas9: host cell modification or proviral editing We need to understand how to more efficiently and feasibly modify host cells to resist infection
60 Broadly neutralizing antibodies (bnabs) Potent neutralization of broad variety of HIV isolates Can be engineered to prolong halflife or improve immune function Bispecific antibodies, dual affinity retargeting antibodies; vectored delivery In human studies: Reduce HIV RNA levels Delay HIV rebound when ART stopped Being tested for HIV prevention, treatment and reservoir reduction gp41 MPER: 2F5, 4E10 10e8 Trimer (gp120/41) 8ANC195 PGT Cell Membrane V1V2 Glycan: PG6, PG16, CH01-04 PGT141-45, PGDM1400 CAP256- VRC26 CD4 Binding Site: VRC01, PG04, CH31 3BNC117, 12A12 CH103, VRC N332 Glycan Supersite: PGT121, PGT Caskey M et al, Nature 2015; Lynch R et al, Sci Transl Med 2015; Mascola JR, CROI 2016, plenary. Bar K et al, NEJM, 2016 Scheid JF et al, Nature, 2016 Caskey M et al, Nat Med, 2017
61 Immune Therapy with bnabs Time to HIV RNA 200 after ART withdrawal VRC01 only slightly delays viral rebound when ART is stopped; viral resistance emerges (ACTG A5340) Bar et al, NEJM, 2016 VRC01 in patients on ART does not clear infected cells or reduce low-level residual viremia (ACTG A5342). Riddler S et al, CROI 2017, abstract 330LB Combining different bnabs is under evaluation May need to combine antibodies or other interventions that mediate killing of infected cells with latency reversing agents that induce HIV expression
62 Although bnabs hold tremendous promise, stable delivery is likely to be a challenge. AAV for sustained bnab delivery!
63 Can we cure HIV? Thus far, HIV has been cured only under extraordinary circumstances HIV cure remains an aspirational goal. Studies underway to test new ways of reversing latency and clearing infected cells. Combination approaches likely to be needed. Increased knowledge of mechanisms of HIV persistence, how to measure the reservoir, and how to reduce the reservoir are needed if we are to cure HIV. Given safety of antiretroviral therapy and uncertainties regarding risks of new interventions, cure studies must adhere to the highest scientific and ethical standards.
64 World AIDS Day, 2013:... the United States should be at the forefront of new discoveries into how to put HIV into long-term remission without requiring lifelong therapies -- or, better yet, to eliminate it completely. Patient: One day I d love to say, I used to have HIV.
65
66
67 Potential Barriers to Cure; Anatomic Sanctuaries Pharmacologic sanctuaries Anatomic sanctuaries Central nervous system Infected cells may persist in lymph node germinal centers 1-2, which exclude cytotoxic T cells Paiardini and Lichterfeld, Nature Med, Fukazawa Y et al, Nat Med Banga R et al, Nat Med, 2016;
68 Fold HIV induction Combination Latency Reversing Agents (LRA): More Effective Induction of HIV expression Single LRA Combo LRA HDAC inhibitor + protein kinase C (PKC) agonist more effective at inducing HIV expression than either is alone However, concerns regarding toxicity of PKC agonists. Laird G et al JCI, 2015
69 Antibody approaches to cure Antibody-based strategies are made possible by an incredible array of antibodies with potent neutralizing activity against a broad range of HIV-1 isolates that have been isolated and characterized over the last several years
70 Strategy # 2: Improve Elimination of HIV Infected Cells ( Kill ) Antibodies to enhance elimination of infected cells Antibody-dependent cytotoxicity? Enhance HIV specific immunity using therapeutic vaccination Ad26/MVA; CMV vector; ChAd/MVA Reverse immune exhaustion of HIV-specific T Cells Anti PD1, Anti PD-L1 Improve function of HIV specific CD8 cells Ex vivo education : HIV Antigen Expanded T cell therapy (HXTC) Genetic modification (chimeric antigen receptor or CAR T cells) Challenge: HIV escape mutations in latently infected cells 1 1 Deng K et al, Nature, 2015
71 Antibody approaches to cure Antibody-based strategies are made possible by an incredible array of antibodies with potent neutralizing activity against a broad range of HIV-1 isolates that have been isolated and characterized over the last several years
72 Summary! Reservoir of long-lived, latently infected CD4+ T cells as well as macrophages (CNS?). Residual viral replication and potential replenishment of viral reservoirs. Reservoir may be dynamic. Cure strategies that target active and dormant viral reservoirs may be required to achieve complete viral elimination.
73 Colleagues/Collaborators/Contributors: University of Miami Natasha Sharova Mark Sharkey Dunja Babic Francesc Cunyat Moira Vignoles David Watkins IRSI Caixa, Barcelona Ventura Clotet Javier Picado Julia Blanco Roger Paredes University of Minnesota Tim Schacker Ashley Haase UCSF Steve Deeks Mike McCune DARE Collaboratory University of Nebraska Courtney Fletcher NIAID NIMH
74 Cautionary Tale - 1 Mississippi child: Born to HIV-infected mother; started on ART within 30 hrs of birth; treated for 18 months, then lost to follow-up When re-engaged in care, undetectable plasma HIV RNA 27 months later: Persaud D et al, NEJM, 2013; Luzuriaga K et al, NEJM 2015.
75 In some surveys, stigma is the major driving motivation for a cure
76 Universal ART, widespread testing and expanded PrEP has reduced new infection by 50%
77
78 Immunotherapy: Curing monkeys with SIV has proven surprisingly easy if you design the study correcting SIV is not HIV, monkeys are not people CMV/HIV vaccine: 50% of vaccinated monkeys who become infected are eventually cured Vaccine + vaccine adjuvant (TLR7 agonists) Broadly neutralizing antibodies during acute infection Broadly neutralizing antibodies + TLR7 agonists
79 The changing face of ART 15 years ago! Today! Tomorrow?
80 Anti PDL1 in HIV infection Double-blind placebo*-controlled study of single dose infusions of BMS with 4 sequential dose-escalating cohorts Cohort 1: 8 participants (6 active / 2 placebo) No effect on HIV RNA in cells or plasma Hypophysitis in one individual at week 36 Study ceased due to preclinical retinal toxicity in macaques Eron et al., J Infect Dis 2016
5/11/2017. HIV Cure Research Questions and a Few Answers
HIV Cure Research Questions and a Few Answers Steven G. Deeks, MD Professor of Medicine University of California San Francisco San Francisco, California FORMATTED: 04/13/17 Financial Relationships With
More informationWith over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the
Towards an HIV Cure Steven G. Deeks, MD Professor of Medicine in Residence HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 22, 2013 1 With over 20 drugs and several
More informationHIV cure: current status and implications for the future
HIV cure: current status and implications for the future Carolyn Williamson, PhD Head of Medical Virology, Faculty Health Sciences, University of Cape Town CAPRISA Research Associate, Centre of Excellence
More informationWhat is the place of the monoclonal antibodies in the clinic?
What is the place of the monoclonal antibodies in the clinic? Dr Julià Blanco 2018/04/26 DISCLOSURE AlbaJuna Therapeutics, S.L. ANTIBODIES IN HIV INFECTION. ANTIVIRAL (NEUTRALIZING) ACTIVITY env THE BROADLY
More informationThe Third D: Long Term Solutions to End the Epidemic. Mitchell Warren Executive Director, AVAC 12 February 2014
The Third D: Long Term Solutions to End the Epidemic Mitchell Warren Executive Director, AVAC 12 February 2014 Key clinical trial milestones: HIV vaccine research First HIV vaccine trial opens Phase
More informationPediatric HIV Cure Research
Pediatric HIV Cure Research HIV Cure Research Training Curriculum Pediatric HIV Cure Research Presented by: Priyanka Uprety,MSPH, PhD Laboratory of Deborah Persaud, MD Johns Hopkins University July 2016
More informationDr Jintanat Ananworanich
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Jintanat Ananworanich US Military HIV Research Program in Bethesda Maryland, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationRecent Insights into HIV Pathogenesis and Treatment: Towards a Cure
Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure Deborah Persaud, M.D. Associate Professor Department of Pediatrics Division of Infectious Diseases Johns Hopkins University School of
More informationA Quarterly Update on HIV Prevention Research. Vol. 8 No. 2
What is it? What could it do? Key Facts Antibodies Passive immunization is the transfer of pre-made antibodies to a person. Passive immunization using today's pre-made antibodies can involve infusion delivered
More informationHIV and Cancer Curative Approaches Cross-disciplinary research. Steven Deeks, MD Professor of Medicine University of California, San Francisco
HIV and Cancer Curative Approaches Cross-disciplinary research Steven Deeks, MD Professor of Medicine University of California, San Francisco Cancer immunotherapy is reshaping a fatal and progressive disease
More informationMHRP. Outline. Is HIV cure possible? HIV persistence. Cure Strategies. Ethical and social considerations. Short video on patients perspectives on cure
Outline Is HIV cure possible? Ø HIV persistence Cure Strategies Ethical and social considerations Short video on patients perspectives on cure A Case of Cure Off ART Treatment Mechanism Lesson The Berlin
More informationApproaching a Cure Daniel R. Kuritzkes, MD
Approaching a Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker is a consultant and/or has received speaking honoraria
More informationCROI 2016 Review: Immunology and Vaccines
Frontier AIDS Education and Training Center CROI 2016 Review: Immunology and Vaccines Meena Ramchandani MD MPH Acting Instructor, University of Washington March 2016 This presentation is intended for educational
More informationThe HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK
The HIV Cure Agenda CHIVA Oct 2016 Nigel Klein Institute of Child Health and Great Ormond Street Hospital, London, UK 2 How frequently is HIV cured? The Berlin patient Restriction of HIV entry CD4 is
More informationState of the ART: HIV Cure where are we now and. where are we going? Jintanat Ananworanich, MD, PhD MHRP
State of the ART: HIV Cure where are we now and ì where are we going? Jintanat Ananworanich, MD, PhD Associate Director for Therapeu1cs Research US Military HIV Research Program (MHRP) Maryland, USA Deputy
More informationHIV Cure Update. Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS
HIV Cure Update Christine Durand, MD 14 de abril de 2016, XIII Conferência Brasil Johns Hopkins University em HIV/AIDS Financial Disclosures Research grants paid to my institution: Gilead Sciences, Bristol
More informationCan HIV be cured? (how about long term Drug free remission?)
Can HIV be cured? (how about long term Drug free remission?) Shirin Heidari International AIDS Society EC Think Tank meeting 27-28 October 2010 Luxemburg HAART can control HIV, cannot eradicate it Life
More informationcure research HIV & AIDS
Glossary of terms HIV & AIDS cure research Antiretroviral Therapy (ART) ART involves the use of several (usually a cocktail of three or more) antiretroviral drugs to halt HIV replication. ART drugs may
More informationCurrent Clinical Therapies for HIV Remission. David Margolis MD UNC HIV Cure Center
Current Clinical Therapies for HIV Remission David Margolis MD UNC HIV Cure Center Aiming for sustained remission off ART Cohen J. Science 214 Luzuriaga et al. NEJM 3;8: 786 Effect of vorinostat, hydroxychloroquine
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationLynn Morris. "Plan B"- bnabs for HIV prevention
"Plan B"- bnabs for HIV prevention Lynn Morris National Institute for Communicable Diseases, a division of the National Health Laboratory Service (NHLS) of South Africa, University of the Witwatersrand,
More informationEarly Antiretroviral Therapy
Early Antiretroviral Therapy HIV Cure Research Training Curriculum HIV and Cure Early ART Presented by: Jintanat Ananworanich, MD, PhD June 2016 The HIV CURE research training curriculum is a collaborative
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationHIV remission after discontinuing ART: is it achievable?
HIV remission after discontinuing ART: is it achievable? Jintanat Ananworanich, MD, PhD Associate Director for Therapeutics Research US Military HIV Research Program Maryland, USA jananworanich@hivresearch.org
More informationRoger Shapiro, MD, MPH Harvard TH Chan School of Public Health Botswana-Harvard Partnership May 2018
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana Roger Shapiro, MD, MPH
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationOverview of the Joint HVTN/HPTN Research Portfolio. Theresa Gamble, PhD HPTN LOC May 15, 2018
Overview of the Joint HVTN/HPTN Research Portfolio Theresa Gamble, PhD HPTN LOC May 15, 2018 1 Joint HVTN/HPTN mab Portfolio HVTN 130/HPTN 089 HVTN 703/HPTN 081 HVTN 704/HPTN 084 AMP (VRC01) HVTN 127/HPTN
More informationPerspective HIV Infection: Advances Toward a Cure
Perspective HIV Infection: dvances Toward a Cure chieving cure of HIV infection requires eliminating all replication-competent virus from the reservoir of latently infected cells or completely inhibiting
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationAIDS free generation. Bob Colebunders Institute of Tropical Medicine
AIDS free generation Bob Colebunders Institute of Tropical Medicine Why this optimism? Rapid scale-up of antiretroviral therapy Treatment can prevent new infections Expanded coverage of programmes to prevent
More informationEradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD
Eradication of HIV infection Not in my lifetime? or Just around the Corner? Michael M. Lederman, MD Conflicts of Interest The pending clinical trials discussed here are funded by grant awards from Gilead
More informationHIV Pathogenesis and Natural History. Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco
HIV Pathogenesis and Natural History Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco Learning Objectives Describe key features of HIV pathogenesis and natural history
More informationBody & Soul. Research update, 25 October 2016
Body & Soul Research update, 25 October 2016 Updates from BHIVA conference on... Cure breakthrough or not? Long acting retrovirals what do they offer? When to start treatment asap post diagnosis? Media
More informationInves&gación básica y curación del VIH-1
Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion
More informationThe potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies
The potential role of PD-1/PD-L1 blockade in HIV Remission and Cure Strategies Stephen Mason Director, Discovery Virology Bristol-Myers Squibb Community Cure Workshop 2015 Sunday, Feb 22, 2015 Seattle,
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationThe Road Towards an HIV Cure
The Road Towards an HIV Cure Authors: Craig McClure and Darien Taylor October 2017 We have done our best to write in plain language. However, an HIV cure treatment glossary may help you to read this article.
More informationPreventive and therapeutic HIV vaccines. Markus Bickel Infektiologikum Frankfurt
Preventive and therapeutic HIV vaccines Markus Bickel Infektiologikum Frankfurt No conflicts to declare Disclosures Background FAQ: by patients and colleagues Publication about promising results, especially
More informationTowards an HIV Cure. Steven G. Deeks Professor of Medicine University of California, San Francisco
Towards an HIV Cure Steven G. Deeks Professor of Medicine University of California, San Francisco Why are we now talking about a cure? Emerging recognition that HAART does not fully restore health and/or
More informationLong-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018
Long-acting Antivirals Where Are We Headed? Are We Ready? Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID May 3, 2018 Global HIV Statistics 2017 People living with HIV in 2016 New HIV infections
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationRichard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting
Richard Jefferys Basic Science, Vaccines & Cure Project Director Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pre-exposure prophylaxis (PrEP)
More informationInvited Review CROI 2018: Advances in Basic Science Understanding of HIV
Invited Review CROI 2018: Advances in Basic Science Understanding of HIV Mario Stevenson, PhD The conference on Retroviruses and Opportunistic Infections represents the most important venue for the dissemination
More informationWorking Group#1: Trial Endpoints, Biomarkers & Definitions
Working Group#1: Trial Endpoints, Biomarkers & Definitions Forum HIV Cure Project: Focus on The Regulatory Pathway June 17, 2014 www.hivforum.org Comments from co-chairs john mellors and mike miller www.hivforum.org
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationImmunodeficiency. (2 of 2)
Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related
More informationMID-TERM EXAMINATION
Epidemiology 227 May 2, 2007 MID-TERM EXAMINATION Select the best answer for the multiple choice questions. There are 75 questions and 11 pages on the examination. Each question will count one point. Notify
More informationAdditional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T
September 8, 2014 Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV- Infected Subjects Treated with SB-728-T
More informationAlternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir
Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir Giuseppe Pantaleo, M.D. Professor of Medicine Head, Division of Immunology and Allergy Executive Director, Swiss Vaccine
More informationBeyond HAART: Outline. HIV-1 Time Line. Outline. Approaches to HIV Eradication 8/15/2013
8/5/203 Beyond HAART: Approaches to HIV Eradication I have no financial conflicts of interest to disclose 8 August 203 Adam Spivak MD Visiting Instructor, Division of Infectious Diseases University of
More information8/10/2017. HIV UPDATE 2017 David M Stein DO, FACOI
HIV UPDATE 2017 David M Stein DO, FACOI 1 Current US HIV data 1.1 million HIV positive 1 out of 7 positive are unaware of their status Highest risk in Gay and Bisexual men, young African American men 2
More informationSustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion
Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing
More informationMicro 301 HIV/AIDS. Since its discovery 31 years ago 12/3/ Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people
Micro 301 HIV/AIDS Shiu-Lok Hu hus@uw.edu December 3, 2012 Since its discovery 31 years ago Acquired Immunodeficiency Syndrome (AIDS) has killed >32 million people In 2011 34.0 million [31.4 35.9 million]
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationHIV Antibody Characterization for Reservoir and Eradication Studies. Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks
HIV Antibody Characterization for Reservoir and Eradication Studies Michael Busch, Sheila Keating, Chris Pilcher, Steve Deeks Blood Systems Research Institute University of California San Francisco, CA
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationModule R: Recording the HIV Reservoir
Module R: Recording the HIV Reservoir Satish K. Pillai, Ph.D. MODULE LEADER Satish Pillai amfar Institute for HIV Cure Research Module R Team Michael Busch Timothy Henrich Sheila Keating Sulggi Lee Henry
More informationClinical Education Initiative HIV CONTROLLERS: IMPLICATIONS FOR HIV CURE/REMISSION. Bruce Walker, MD
Clinical Education Initiative Support@ceitraining.org HIV CONTROLLERS: IMPLICATIONS FOR HIV CURE/REMISSION Bruce Walker, MD 6/23/2017 HIV Controllers: Implications for HIV Cure/Remission [video transcript]
More informationImpact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir
Impact of Vorinostat Treatment of Non- Hodgkin s Lymphoma on HIV-1 Latent Reservoir Adam Capoferri, Juan Carlos Ramos, Daniel Xu, Daniel I.S. Rosenbloom, Janet D. Siliciano, Robert F. Siliciano, Ariela
More informationHIV cure strategies: interventions, endpoints and ethics
HIV cure strategies: interventions, endpoints and ethics Professor Sharon R Lewin, FRACP, PhD, FAHMS Fourth Joint Conference of BHIVA with BASSH, April 17-20, Edinburgh International Conference Centre,
More informationHIV remission: viral suppression in the absence of ART. Sarah Fidler Brian Gazzard Lecture BHIVA 2016
HIV remission: viral suppression in the absence of ART Sarah Fidler Brian Gazzard Lecture BHIVA 2016 Disclosures: My institution receives funding for research from MSD, GSK, ViiV, Gilead Summary of talk
More informationHIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies
HIV Reservoirs in Developing Countries: Implication for HIV CURE Strategies 10 th INTEREST CONFERENCE 2016, 3-6 TH May 2016, Yaoundé, Cameroon Cissy Kityo 1 ; Thomas Schacker 2 ; Francis Ssali 1 ; Jeffrey
More informationThe injectables: a new silver bullet?
The injectables: a new silver bullet? Geneva October 6 Francois Venter Wits Reproductive Health and HIV Institute Thanks Clinical Care Options, Helen Rees, Joe Eron, Wits RHI sex worker team Disclosures
More informationHIV cure research: current strategies and challenges. current strategies to eliminate latently infected cells 2/10/2015
Viral load // HIV cure research: current strategies and challenges Sharon R Lewin Director, Doherty Institute for Infection and Immunity, The University of Melbourne, Consultant physician, The Alfred,
More informationEarly Antiretroviral Therapy in Newborns: Opportunities and Challenges. Ellen Gould Chadwick MD Northwestern University Feinberg School of Medicine
Early Antiretroviral Therapy in Newborns: Opportunities and Challenges Ellen Gould Chadwick MD Northwestern University Feinberg School of Medicine Conflict of Interest Disclosures for Ellen Chadwick MD
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationBroadly Neutralizing Antibodies for HIV Eradication
DOI 10.1007/s11904-016-0299-7 HIV PATHOGENESIS AND TREATMENT (AL LANDAY, SECTION EDITOR) Broadly Neutralizing Antibodies for HIV Eradication Kathryn E. Stephenson 1,2 & Dan H. Barouch 1,2 # The Author(s)
More information, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic
1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in
More informationEstablishment and Targeting of the Viral Reservoir in Rhesus Monkeys
Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys Dan H. Barouch, M.D., Ph.D. Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Ragon Institute of MGH, MIT,
More informationIntroduction to HIV/AIDS
HIV/AIDS Seminar 5 Welcome Back Introduction to HIV/AIDS History of HIV/AIDS It is now thought that HIV came from a similar virus found in chimpanzees - SIV. HIV probably entered North America around 1970
More informationStructure of HIV. Virion contains a membrane envelope with a single viral protein= Env protein. Capsid made up of Gag protein
Structure of HIV Virion contains a membrane envelope with a single viral protein= Env protein Important in receptor recognition Capsid made up of Gag protein (group-specific antigen) Icosahedral Interior
More informationProfessor Jonathan Weber
HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust Multidisciplinary Event to mark World AIDS Day 2011 British HIV Association (BHIVA) 2011 HIV/AIDS at 30: Back to the Future BHIVA / Wellcome Trust
More informationEMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV. (Summary of the recommendations from an Enterprise Working Group)
AIDS Vaccine 07, Seattle, August 20-23, 2007 EMERGING ISSUES IN THE HUMORAL IMMUNE RESPONSE TO HIV (Summary of the recommendations from an Enterprise Working Group) The Working Group Reston, Virginia,
More informationSAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL
SAMRC S RESPONSE TO HIV & TB: WALKING THE TALK: MOVING TO CONTROL Glenda Gray President & CEO SAMRC 1 SA AIDS 2017 Durban 15 June 2017 Partner logo LEADERSHIP IN A TIME OF UNCERTAINTY 2 BASELINE BUDGET
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationCHAPTER - IV OBJECTIVES OF THE STUDY
CHAPTER - IV OBJECTIVES OF THE STUDY 4.1 BACKGROUND Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) commonly referred to as HIV & AIDS have emerged as being
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationCell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir
The Journal of Infectious Diseases SUPPLEMENT ARTICLE Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir James L. Riley 1 and Luis J. Montaner 2 1 Department of Microbiology
More informationEradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia
Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia Dr Bonaventura Clotet Transparency declaration I have served during the past 2 years as
More informationBEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
BEAT-HIV Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy We are pleased to announce that the National Institutes of Health (NIH) has awarded nearly $23 million to co-principal
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationACT UP (AIDS Coalition To Unleash Power): HIV/AIDS activist group founded in 1987 in New York City.
GLOSSARY OF TERMS ACT UP (AIDS Coalition To Unleash Power): HIV/AIDS activist group founded in 1987 in New York City. Agitprop: a term used to describe political art meant to agitate and spread propaganda.
More informationSupporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
More informationPROSPECTS FOR HIV CURE IN ADULTS. Nov 11 th 2013 John Frater
PROSPECTS FOR HIV CURE IN ADULTS FIS 2013 Nov 11 th 2013 John Frater April 29 th 2013; Telegraph online THE COMPONENTS OF A CURE. What is cure? Issues to consider: Post treatment control the benefit of
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationIsolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient
Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient Amanda Fabra García, Carolina Beltrán Pavez, Alberto Merino Mansilla, Cristina Xufré, Isabel
More informationFunctional cure of HIV: the scale of the challenge. *, David S. Khoury 1
AnaLysIs Functional cure of HIV: the scale of the challenge Miles P. Davenport 1 *, David S. Khoury 1, Deborah Cromer 1, Sharon R. Lewin 2,3, Anthony D. Kelleher 1 and Stephen J. Kent 2,3,4,5 Abstract
More informationCh 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems
Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Highlight Disease: Malaria World s dominant protozoal disease. Four species of Plasmodium: P. falciparum (malignant), P. vivax (begnin),
More informationSangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia
October 28, 2013 Sangamo BioSciences Presents Clinical Data From HIV Study Demonstrating Sustained Control Of Viremia Reduction of Viral Load at or Below Limit of Detection Ongoing at 14 Weeks Additional
More informationSangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies
December 11, 2015 Sangamo BioSciences Presents Phase 2 Clinical Data From Two SB-728-T HIV Studies Preliminary Data Suggest Adenoviral Delivery Method Superior for Immune Stimulation and Control of Viral
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationHIV Eradication and the Quest for Functional Cure
HIV Eradication and the Quest for Functional Cure Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures Consultant and/or research support
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More information